Waters Corp (WAT) Puts a Bigger Footprint on Q1 2026, Lifts Revenue Forecast as BD&S Acquisition Flows Through

Key numbers at a glance: revenue, EPS, and the acquisition tailwind

The quarter produced total reported revenue of $1.267 billion, with organic revenue up 13% as reported and 11% in constant currency. The strong top line was helped by $520 million of Biosciences and Diagnostic Solutions revenue since the closing of the acquisition on February 9, 2026. Waters notes the acquisition contributed meaningfully to the results, effectively expanding the company’s revenue base for the quarter and setting up a broader revenue mix for 2026.

On the bottom line, GAAP diluted EPS came in at a loss of $0.87 for the quarter, reflecting acquisition-related charges, including amortization of acquired intangibles and inventory step-ups. By contrast, adjusted EPS rose 20% year over year to $2.70, underscoring what the company frames as ongoing operating discipline and revenue strength. In investor terms, this creates a classic split: an earnings surprise on the revenue and adjusted earnings front, but a GAAP EPS that looks structurally dragged by one-time accounting effects tied to the BD&S deal.

What changed with the acquisition and how it shapes guidance

The BD&S deal is now baked into Waters’ baseline for 2026. Management highlighted that the acquisition aligns with a broader push: expanding the company’s Analytical Sciences, Biosciences, and Diagnostics capabilities while delivering cross‑portfolio revenue synergies. The company has raised its full-year organic constant currency revenue growth guidance to 6.5%–8.0% and now expects acquired revenues to contribute about $3.035 billion in reported revenue for 2026. The corresponding adjusted EPS guidance was lifted to a range of $14.40–$14.60 for the full year, signaling double-digit growth on the adjusted metric despite higher closing-date leverage and integration costs.

Analysts and investors will likely weigh the implied EPS consensus against this broader revenue trajectory and the mix shift toward larger, acquired franchises. If the market skews toward the adjusted EPS narrative, the stock could see support on the back of the clearer profitability pathway even as GAAP EPS remains depressed by purchase accounting charges. In other words, investors may look past the one-time accounting impacts to the durable earnings power implied by the combined platform.

Division-by-division snapshot and what it implies for growth trajectories

Waters’ quarterly breakdown highlighted strong execution within the company’s core franchises. The Analytical Sciences Division (ASD), the former Waters core, delivered revenue of $607 million for the quarter, up from $534 million in Q1 2025. The Biosciences Division (WBD), rebranded after the BD acquisition, posted $232 million of revenue on an owned-period basis within the quarter. The Advanced Diagnostics Division (ADx) was also highlighted, though the press materials reserved the most detail for the ASD and WBD results given the strategic significance of the BD integration.

Together, these results illustrate Waters’ strategy: leverage existing high-margin, high-growth segments while integrating large-scale acquisitions to accelerate revenue growth. The 13% reported organic growth and the higher-end 6.5%–8.0% 2026 organic growth guidance suggest the combined business should see continued momentum as the integration matures and the product cadence accelerates with new offerings.

The management view: leadership signals and strategic posture

In a client-facing cadence that feels more like a narrative than a quarterly financial sprint, Udit Batra, Ph.D., Waters’ President and CEO, framed the results as evidence of strong execution and a healthy pipeline of launches and upgrades. The rhetoric underscored a belief that the integration is progressing smoothly, enabling revenue synergies and a sharper focus on forthcoming product introductions. The tone hints at a longer horizon in which Waters leverages the BD acquisition to push double-digit growth on a sustained basis, even as near-term GAAP metrics reflect one-time integration costs.

Implications for Waters and peers: what to watch next

For Waters, the 2026 revenue forecast hinges on continued organic growth, successful assimilation of the acquired businesses, and favorable currency dynamics. The lift in guided revenue and adjusted EPS signals a constructive view of the year ahead, but investors will monitor margins and the pace of integration-driven cost leverage. In the near term, the GAAP EPS readings may remain depressed by amortization and inventory step-ups, a common trade-off when pursuing acceleration through acquisitions.

Sector peers will parse Waters’ trajectory as a case study in post-merger growth timing. If the BD acquisition translates into early cross-selling and operational improvements, competitors could accelerate their own M&A or partner strategies to preserve or enhance their growth runways. The key question for the sector is whether Waters’ synergy-driven expansion can sustain double-digit adjusted EPS growth as integration costs normalize and the revenue mix tilts toward the now-embedded BD assets.

In the near term, analysts’ EPS consensus for Waters could shift upward as the market digests a stronger revenue forecast and a clearer path to operating leverage. The interplay between organic growth, acquisition-driven revenue, and the normalization of GAAP charges will be pivotal in determining how Waters’ shares and its peers are valued in the coming quarters.